MENU
+Compare
SPRO
Stock ticker: NASDAQ
AS OF
May 9, 04:51 PM (EDT)
Price
$0.62
Change
+$0.05 (+8.77%)
Capitalization
32.15M

SPRO Spero Therapeutics Forecast, Technical & Fundamental Analysis

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm... Show more

SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for SPRO with price predictions
May 08, 2025

SPRO's Stochastic Oscillator is staying in oversold zone for 6 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRO advanced for three days, in of 207 cases, the price rose further within the following month. The odds of a continued upward trend are .

SPRO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on April 29, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on SPRO as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for SPRO turned negative on May 02, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SPRO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.715) is normal, around the industry mean (14.243). P/E Ratio (10.751) is within average values for comparable stocks, (62.770). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.866). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (1.164) is also within normal values, averaging (253.449).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SPRO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

SPRO is expected to report earnings to fall 30.26% to -26 cents per share on May 13

Spero Therapeutics SPRO Stock Earnings Reports
Q1'25
Est.
$-0.26
Q4'24
Missed
by $0.02
Q3'24
Beat
by $0.18
Q2'24
Beat
by $0.05
Q1'24
Missed
by $0.12
The last earnings report on March 27 showed earnings per share of -37 cents, missing the estimate of -36 cents. With 43.57K shares outstanding, the current market capitalization sits at 32.15M.
A.I. Advisor
published General Information

General Information

a developer of novel therapies for the treatment of resistant bacterial infections

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
675 Massachusetts Avenue
Phone
+1 857 242-1600
Employees
46
Web
https://www.sperotherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
COEP8.760.49
+5.93%
Coeptis Therapeutics Holdings Inc
ATUS2.770.12
+4.53%
Altice USA
ABG225.868.02
+3.68%
Asbury Automotive Group
GEHC70.501.68
+2.44%
GE HealthCare Technologies
IPI37.940.09
+0.24%
Intrepid Potash

SPRO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRO has been loosely correlated with RCKT. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRO jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRO
1D Price
Change %
SPRO100%
-0.52%
RCKT - SPRO
34%
Loosely correlated
+11.57%
MGTX - SPRO
34%
Loosely correlated
+1.11%
KYMR - SPRO
33%
Loosely correlated
+5.70%
XENE - SPRO
33%
Poorly correlated
+0.59%
CHRS - SPRO
32%
Poorly correlated
+4.87%
More